摘要
目的评价疗效满意度问卷在慢性阻塞性肺疾病(COPD)稳定期的信度、效度和反应度。方法选取2008年1-10月河南中医学院第一附属医院呼吸科收治的155例COPD稳定期患者进行问卷调查,以Cronbach’α、Guttman分半系数和重测信度评价问卷信度,以内容效度和结构效度评价问卷效度,以治疗前后量表均分比较评价反应度,以应答率评价可行性。结果疗效满意度测评问卷在COPD稳定期的Cronbach’α系数为0.906、Guttman分半系数为0.758,工作生活能力、临床症状、治疗效果、治疗方便的Cronbach’α系数分别为0.905、0.645、0.788、0.793;问卷各领域与其所包含的条目相关系数绝对值在0.70～0.87之间,共提取3个公因子;各领域积分改善均为较大效应尺度变化;问卷有效应答率91.2%。结论疗效满意度问卷在COPD稳定期的应用具有良好的信度,内容效度较好,结构效度一般,能较好地区分治疗效果。
Objective To evaluate the reliability, validity and responsibility of the efficacy satisfaction scale for COPD patients at stable stage. Methods One hundred and fifty-five COPD patients at stable stage were selected from January to October of 2008. All subjects came from The First Affiliated Hospital of Heart College of TCM. The Cronbach＇ a coefficient, Guttman split-half coefficient and re-test reliability were used as the indexes to reflect the reliability of the scale. The content validity and the construct validity were used to evaluate the validity of the sacle. The average score between pre-treatment and post-treatment was compared to evaluate the feasibility. Results The Cronbach＇a coefficinent and Guttman split-half coefficinent of the efficacy satisfaction scale for COPD at stable stage respective was 0.906 and 0.758. The Cronbach＇a coefficinent of the four domains respective were 0.905 （working and life ability）, 0.645 （clinical symptoms）, 0.788 （efficacy） and 0.793 （therapy convenience） for the efficacy satisfaction scale. The correlation coefficient between the four domains and it＇s items were within 0.70-0.87. The factor analysis of the scale extracted three common factors. The scores improvement with four domains was of great effect size change. The effective response rate was 91.2%. Conclusion The efficacy satisfaction scale for COPD patients at stable stage has better reliability, good content validity and common construct validity which could better distinguish therapeutic efficacy.
出处
《中国中医药信息杂志》
CAS
CSCD
2010年第6期8-10,共3页
Chinese Journal of Information on Traditional Chinese Medicine
基金
国家"十一五"科技支撑计划(2006BA104A13-02)
